Sex-Specific Differences in Patients with IDH1-Wild-Type Grade 4 Glioma in the ReSPOND Consortium
Sree Gongala,Jose A Garcia,Nisha Korakavi,Nirav Patil,Hamed Akbari,Andrew Sloan,Jill S Barnholtz-Sloan,Jessie Sun,Brent Griffith,Laila M Poisson,Thomas C Booth,Rajan Jain,Suyash Mohan,MacLean P Nasralla,Spyridon Bakas,Charit Tippareddy,Josep Puig,Joshua D Palmer,Wenyin Shi,Rivka R Colen,Aristeidis Sotiras,Sung Soo Ahn,Yae Won Park,Christos Davatzikos,Chaitra Badve,ReSPOND Consortium,Kristin A Waite,Arnab Chakravarti,William Taylor,Zev A Binder,Stephen Bagley,Arati Desai,Donald M O'Rourke,Steven Brem,Adam P Dicker,Ayesha Ali,Spencer Liem,Muhammad Sharif,Adam E Flanders,Pamela LaMontagne,Mikhail Milchenko,Arash Nazeri,Hassan Fathallah-Shaykh,Jaume Capellades,Lisa Rogers,Alysha Chelliah,Matthew Lee,Michel Bilello,Ujjwal Baid,Elizabeth Mamourian,Anahita Fathi Kazerooni,Chiharu Sako,Robert A Lustig,Seung-Koo Lee,Jong Hee Chang,Gaurav Shukla,Murat Ak,Santiago Cepeda,Benedikt Wiestler,Anna Lusia Di Stefano,Graeme F Woodworth,Peter I Kamel,Pallavi Tiwari,Mariam Aboian,Jeffrey Rudie,Andreas Rauschecker,Yoon Seong Choi,Aaron M Rulseh,Abhishek Mahajan,Carmen Balana,Daniel S Marcus,Dominic DiCostanzo,Golestan Karami,Javier Villanueva-Meyer,Kazuhiko Kurozumi,Shinichiro Koizumi,Toru Kawakatsu,Laveniya Satgunaseelan,Pablo Valdes,Victor M PerezGarcia,Ryoji Imoto,Yoshihiro Otani,Yuji Matsumoto,Elias R Melhem,Evan Calabrese,Greory S Alexander,Jerrold Boxerman,Jiao Zhicheng,Kimberley L Alexander,Orazio Santo Santonocito,Susan Chang,Joseph Lombardo
DOI: https://doi.org/10.3174/ajnr.A8319
2024-09-09
Abstract:Background and purpose: Understanding sex-based differences in patients with glioblastoma is necessary for accurate personalized treatment planning to improve patient outcomes. Our purpose was to investigate sex-specific differences in molecular, clinical, and radiologic tumor parameters, as well as survival outcomes in patients with glioblastoma, isocitrate dehydrogenase-1 wild-type (IDH1-WT), grade 4. Materials and methods: Retrospective data of 1832 patients with glioblastoma, IDH1-WT with comprehensive information on tumor parameters was acquired from the Radiomics Signatures for Precision Oncology in Glioblastoma consortium. Data imputation was performed for missing values. Sex-based differences in tumor parameters, such as age, molecular parameters, preoperative Karnofsky performance score (KPS), tumor volumes, epicenter, and laterality were assessed through nonparametric tests. Spatial atlases were generated by using preoperative MRI maps to visualize tumor characteristics. Survival time analysis was performed through log-rank tests and Cox proportional hazard analyses. Results: Glioblastoma was diagnosed at a median age of 64 years in women compared with 61.9 years in men (false discovery rate [FDR] = 0.003). Men had a higher KPS (above 80) as compared with women (60.4% women versus 69.7% men, FDR = 0.044). Women had lower tumor volumes in enhancing (16.7 cm3 versus 20.6 cm3 in men, FDR = 0.001), necrotic core (6.18 cm3 versus 7.76 cm3 in men, FDR = 0.001), and edema regions (46.9 cm3 versus 59.2 cm3 in men, FDR = 0.0001). The right temporal region was the most common tumor epicenter in the overall population. Right as well as left temporal lobes were more frequently involved in men. There were no sex-specific differences in survival outcomes and mortality ratios. Higher age, unmethylated O6-methylguanine-DNA-methyltransferase promoter and undergoing subtotal resection increased the mortality risk in both men and women. Conclusions: Our study demonstrates significant sex-based differences in clinical and radiologic tumor parameters of patients with glioblastoma. Sex is not an independent prognostic factor for survival outcomes and the tumor parameters influencing patient outcomes are identical for men and women.